1. Sivarajan G, Borofsky MS, Shah O, Lingeman JE, Lepor H. The role of minimally invasive surgical techniques in the management of large-gland benign prostatic hypertrophy. Rev Urol 2015;17:140-9.
2. Vuichoud C, Loughlin KR. Benign prostatic hyperplasia: epidemiology, economics and evaluation. Can J Urol 2015;22(Suppl 1):1-6.
3. From the Centers for Disease Control and Prevention. Public health and aging: trends in aging-United States and worldwide. JAMA. 2003;289:1371-3.
4. Abrams P, Chapple C, Khoury S, Roehrborn C, de la Rosette J, International Scientific Committee. Evaluation and treatment of lower urinary tract symptoms in older men. J Urol 2009;181:1779-87.
6. McVary KT, Roehrborn CG, Avins AL, Barry MJ, Bruskewitz RC, Donnell RF, et al. American Urological Association Guideline: management of benign prostatic hyperplasia (BPH). Linthicum (ML): American Urological Association Education and Research, Inc.; 2010.
7. Oelke M, Bachmann A, Descazeaud A, Emberton M, Gravas S, Michel MC, et al. EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol 2013;64:118-40.
8. Reich O, Gratzke C, Bachmann A, Seitz M, Schlenker B, Hermanek P, et al. Morbidity, mortality and early outcome of transurethral resection of the prostate: a prospective multicenter evaluation of 10,654 patients. J Urol 2008;180:246-9.
9. Bach T, Muschter R, Sroka R, Gravas S, Skolarikos A, Herrmann TR, et al. Laser treatment of benign prostatic obstruction: basics and physical differences. Eur Urol 2012;61:317-25.
10. Elzayat EA, Elhilali MM. Holmium laser enucleation of the prostate (HoLEP): the endourologic alternative to open prostatectomy. Eur Urol 2006;49:87-91.
11. Kuntz RM. Current role of lasers in the treatment of benign prostatic hyperplasia (BPH). Eur Urol 2006;49:961-9.
12. Naspro R, Bachmann A, Gilling P, Kuntz R, Madersbacher S, Montorsi F, et al. A review of the recent evidence (2006-2008) for 532-nm photoselective laser vaporisation and holmium laser enucleation of the prostate. Eur Urol 2009;55:1345-57.
13. Kluivers KB, Riphagen I, Vierhout ME, Brolmann HA, de Vet HC. Systematic review on recovery specific qual-ity-of-life instruments. Surgery 2008;143:206-15.
14. Myles PS, Hunt JO, Nightingale CE, Fletcher H, Beh T, Tanil D, et al. Development and psychometric testing of a quality of recovery score after general anesthesia and surgery in adults. Anesth Analg 1999;88:83-90.
16. Magistro G, Stief CG, Woo HH. Mini-review: what is new in Urolift? Eur Urol Focus 2018;4:36-9.
17. Roehrborn CG, Barkin J, Gange SN, Shore ND, Giddens JL, Bolton DM, et al. Five year results of the prospective randomized controlled prostatic urethral L.I.F.T. study. Can J Urol 2017;24:8802-13.
19. Srinivasan A, Wang R. An update on minimally invasive surgery for benign prostatic hyperplasia: techniques, risks, and efficacy. World J Mens Health. 2019 Aug 20 [Epub].
https://doi.org/10.5534/wjmh.190076.
20. Magistro G, Chapple CR, Elhilali M, Gilling P, McVary KT, Roehrborn CG, et al. Emerging minimally invasive treatment options for male lower urinary tract symptoms. Eur Urol 2017;72:986-97.
21. Chung ASJ, Woo HH. Update on minimally invasive surgery and benign prostatic hyperplasia. Asian J Urol 2018;5:22-7.
22. Jones P, Rajkumar GN, Rai BP, Aboumarzouk OM, Cleaveland P, Srirangam SJ, et al. Medium-term outcomes of Urolift (Minimum 12 Months Follow-up): evidence from a systematic review. Urology 2016;97:20-4.
23. Roehrborn CG, Rukstalis DB, Barkin J, Gange SN, Shore ND, Giddens JL, et al. Three year results of the prostatic urethral L.I.F.T. study. Can J Urol 2015;22:7772-82.
24. Sanchez-Gomez LM, Polo-deSantos M, Gomez-Sancha F, Luengo-Matos S. Efficacy and safety of the urolift® system for the treatment of benign prostate hyperplasia symptoms: systematic review. Actas Urol Esp 2015;39:311-9.
26. Kim JH, Lee KS, Kim TH. Evaluation of clinical outcomes of prostatic urethral lift for benign prostatic hyper-plasia: an asian population study. World J Mens Health 2019 Jul 30 [Epub].
https://doi.org/10.5534/wjmh.190015.
29. Dixon C, Cedano ER, Pacik D, Vit V, Varga G, Wagrell L, et al. Efficacy and safety of Rezum system water vapor treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia. Urology 2015;86:1042-7.
30. Mynderse LA, Hanson D, Robb RA, Pacik D, Vit V, Varga G, et al. Rezum system water vapor treatment for lower urinary tract symptoms/benign prostatic hyperplasia: validation of convective thermal energy transfer and characterization with magnetic resonance imaging and 3-di-mensional renderings. Urology 2015;86:122-7.
31. McVary KT, Rogers T, Roehrborn CG. Rezum water vapor thermal therapy for lower urinary tract symptoms associated with benign prostatic hyperplasia: 4-year results from randomized controlled study. Urology 2019;126:171-9.
32. McVary KT, Gange SN, Gittelman MC, Goldberg KA, Patel K, Shore ND, et al. Minimally invasive prostate con-vective water vapor energy ablation: a multicenter, randomized, controlled study for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 2016;195:1529-38.
33. Roehrborn C, Gange S, Gittelman M. PD23-10. Convective radiofrequency thermal therapy: durable two-year outcomes of a randomized controlled and prospective crossover study to relieve lower urinary tract symptoms due to benign prosᄀtatic hyperplasia. J Urol 2017;197(Suppl):e450-1.
34. McVary KT, Gange SN, Gittelman MC, Goldberg KA, Patel K, Shore ND, et al. Erectile and ejaculatory function preserved with convective water vapor energy treatment of lower urinary tract symptoms secondary to benign pro-static hyperplasia: randomized controlled study. J Sex Med 2016;13:924-33.
35. Faber K, de Abreu AL, Ramos P, Aljuri N, Mantri S, Gill I, et al. Image-guided robot-assisted prostate ablation using water jet-hydrodissection: initial study of a novel technology for benign prostatic hyperplasia. J Endourol 2015;29:63-9.
37. Nair SM, Pimentel MA, Gilling PJ. Evolving and inves-tigational therapies for benign prostatic hyperplasia. Can J Urol 2015;22(Suppl 1):82-7.
38. Gilling P, Anderson P, Tan A. Aquablation of the prostate for symptomatic benign prostatic hyperplasia: one-year results. J Urol 2017;197:1565-72.
39. Gilling P, Reuther R, Kahokehr A, Fraundorfer M. Aquablation - image-guided robot-assisted waterjet ablation of the prostate: initial clinical experience. BJU Int 2016;117:923-9.
40. Gilling P, Barber N, Bidair M, Anderson P, Sutton M, Aho T, et al. WATER: A douole-blind, randomized, controlled trial of Aquablation® vs transurethral resection of the prostate in benign prostatic hyperplasia. J Urol 2018;199:1252-61.
41. Desai M, Bidair M, Zorn KC, Trainer A, Arther A, Kramolowsky E, et al. Aquablation for benign prostatic hyperplasia in large prostates (80-150 mL): 6-month results from the WATER II trial. BJU Int 2019;124:321-8.